4
INTRODUCTION
Primary lung cancer (PLC) is one of the most common
malignancies today and is the leading cause of death in cancer. In
Vietnam, lung cancer (LC) has increased rapidly. According to the
Global Cancer Research Organization (GLOBOCAN) in 2018, there
are 23,667 new people in the country with LC. About 90% of
patients with PLC die in the first year. Recently, CIZ1, a gene coding
for intracellular protein involved in the initiation of DNA replication,
has been studied. CIZ1b, a variant of CIZ1, manifests itself in non-
small cell lung cancer (NSCLC). Besides, Vascular endothelial
growth factor (VEGF) plays a very important role in tumour growth.
EGFR mutation is a valuable molecular target in the use of Tyrosine
Kinase inhibitors - TKIs in treatment of NSCLC. Recently, the role
of Virus Merkel cell (Merkel cell polyomavirus, MCV) in LC has
been mentioned and researched. We conducted the project:
"Studying the mRNA expression of CIZ1b, VEGF and EGFR
mutations with Merkel cell virus infection in patients with non-
small cell lung cancer" with these objectives:
1. Assessed the level of mRNA expression of CIZ1b, VEGF, EGFR
mutations and the rate of Merkel cell infection in patients with non-
small cell lung cancer.
2. Analysed the relationship between the level of mRNA expression
of CIZ1b, VEGF, EGFR mutations with Merkel cell infection and
some clinical and subclinical symptoms in patients with non-small
cell lung cancer.
Rationale of the Study
Study on mRNA expression of CIZ1b, VEGF, EGFR mutation and
Merkel cell virus (MCV) infection contribute to early diagnosis,
identify the cause of disease and its application in monitoring and
treatment of NSCLC, contribute to improving the quality of life,
